Terms: = Skin cancer AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76 AND Clinical Outcome
333 results:
1. clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract] [Full Text] [Related]
2. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
3. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
Gambichler T; Iordanou M; Becker JC; Susok L
Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
[TBL] [Abstract] [Full Text] [Related]
4. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
5. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
6. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
8. Emilin2 fosters vascular stability by promoting pericyte recruitment.
Fejza A; Camicia L; Carobolante G; Poletto E; Paulitti A; Schinello G; Di Siena E; Cannizzaro R; Iozzo RV; Baldassarre G; Andreuzzi E; Spessotto P; Mongiat M
Matrix Biol; 2023 Sep; 122():18-32. PubMed ID: 37579864
[TBL] [Abstract] [Full Text] [Related]
9. Effect of lidocaine spray on reliving non-coring needle puncture-related pain in patients with totally implantable venous access port: a randomized controlled trial.
Zhu Y; Niu S; Zhang Y; Zhang H; Chang J; Ye L
Support Care Cancer; 2023 Jul; 31(8):452. PubMed ID: 37421451
[TBL] [Abstract] [Full Text] [Related]
10. BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
Mandalà M; Palmieri G; Ludovini V; Baglivo S; Marasciulo F; Castiglione F; Gili A; Osella Abate S; Rubatto M; Senetta R; Avallone G; Ribero S; Romano L; Pimpinelli N; de Giorgi V; Roila F; Pisano M; Casula M; Manca A; Sini MC; Massi D; Quaglino P;
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):1991-1998. PubMed ID: 37335879
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic Factors of Pretreatment Magnetic Resonance Imaging for Predicting clinical outcome in Patients With Parotid Gland cancer.
Ando T; Kato H; Shibata H; Ogawa T; Noda Y; Hyodo F; Matsuo M
J Comput Assist Tomogr; 2023 May-Jun 01; 47(3):507-513. PubMed ID: 37185018
[TBL] [Abstract] [Full Text] [Related]
12. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial.
Kent P; Haines T; O'Sullivan P; Smith A; Campbell A; Schutze R; Attwell S; Caneiro JP; Laird R; O'Sullivan K; McGregor A; Hartvigsen J; Lee DA; Vickery A; Hancock M;
Lancet; 2023 Jun; 401(10391):1866-1877. PubMed ID: 37146623
[TBL] [Abstract] [Full Text] [Related]
13. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
Garcia-Donas J; Martínez-Urbistondo D; Velázquez Kennedy K; Villares P; Barquin A; Dominguez A; Rodriguez-Moreno JF; Caro E; Suarez Del Villar R; Nistal-Villan E; Yagüe M; Ortiz M; Barba M; Ruiz-Llorente S; Quiralte M; Zanin M; Rodríguez C; Navarro P; Berraondo P; Madurga R
Front Immunol; 2023; 14():1156603. PubMed ID: 37143685
[TBL] [Abstract] [Full Text] [Related]
14. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
15. Type 2 Diabetes Mellitus and Efficacy outcomes from Immune Checkpoint Blockade in Patients with cancer.
Cortellini A; D'Alessio A; Cleary S; Buti S; Bersanelli M; Bordi P; Tonini G; Vincenzi B; Tucci M; Russo A; Pantano F; Russano M; Stucci LS; Sergi MC; Falconi M; Zarzana MA; Santini D; Spagnolo F; Tanda ET; Rastelli F; Giorgi FC; Pergolesi F; Giusti R; Filetti M; Lo Bianco F; Marchetti P; Botticelli A; Gelibter A; Siringo M; Ferrari M; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Ghidini M; Nigro O; Grossi F; De Tursi M; Di Marino P; Queirolo P; Bracarda S; Macrini S; Inno A; Zoratto F; Veltri E; Spoto C; Vitale MG; Cannita K; Gennari A; Morganstein DL; Mallardo D; Nibid L; Sabarese G; Brunetti L; Perrone G; Ascierto PA; Ficorella C; Pinato DJ
Clin Cancer Res; 2023 Jul; 29(14):2714-2724. PubMed ID: 37125965
[TBL] [Abstract] [Full Text] [Related]
16. Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy.
Oertel M; Borrmann K; Baehr A; Eich HT; Greve B
Radiat Oncol; 2022 Nov; 17(1):194. PubMed ID: 36443849
[TBL] [Abstract] [Full Text] [Related]
17. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
[No Abstract] [Full Text] [Related]
18. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract] [Full Text] [Related]
19. Cigarette smoking and adverse health outcomes in patients treated with maintenance dialysis.
Bek SG; Marschner S; Sud K; Johnson DW; Chow CK; Hawley C; Pilmore H; Wong G; Lim W; Lee VW
Nephrology (Carlton); 2023 Jan; 28(1):21-27. PubMed ID: 36222366
[TBL] [Abstract] [Full Text] [Related]
20. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
[TBL] [Abstract] [Full Text] [Related]
[Next]
